tiprankstipranks
Amplia Therapeutics Partners with Next&Bio for Cancer Research
Company Announcements

Amplia Therapeutics Partners with Next&Bio for Cancer Research

Amplia Therapeutics Ltd. (AU:ATX) has released an update.

Don't Miss Our Christmas Offers:

Amplia Therapeutics has entered into a preclinical collaboration with Korean drug screening company Next&Bio to study the effects of its FAK inhibitors in combination with kRas inhibitors for treating pancreatic cancer. This partnership aims to explore new commercial opportunities by testing these compounds on patient-derived cancer cells. Amplia’s strategic move could potentially enhance the development of targeted therapies in the fight against cancer.

For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskAmplia Therapeutics Secures $13 Million in Capital Raise
TipRanks Australian Auto-Generated NewsdeskAmplia Therapeutics Announces Director’s Increased Shareholding
TipRanks Australian Auto-Generated NewsdeskAmplia Therapeutics Announces Director’s Share Acquisition
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App